Aida Rouzmehr
Material Science Product Lead Genentech
Aida Rouzmehr is the Material Science Product Lead in Genentech. She provides strategic end to end oversight to atmp materials across the Individualized & Cell Therapy portfolio, focusing on material understanding, oversight, and quality assurance in partnership with technical development teams. Aida has over a decade of experience in process development and engineering with expertise in single use technologies, technology transfer, start-up operations, and technical development within the large molecule biologics, advanced therapy medicinal products (ATMPs) and medical device industries. Aida holds Bachelor’s and Master’s degrees in Chemical Engineering and Materials Science from the University of California, Irvine.
Seminars
As cell and gene therapies evolve, so too does the complexity of their raw material requirements. Introducing a raw material into an existing CGT process demands a coordinated approach across technical, quality, regulatory, and supply chain functions. This session will cover an end-to-end frame work of adding a new supplier into your manufacturing process, working through hypothetical scenarios to identify the biggest challenges as we head into the main conference days.
- Gain a practical framework for assessing the need for a new raw material and initiating vendor scouting and evaluation
- Understand key strategies for technical onboarding, including comparability studies, risk assessments, and process validation
- Explore how to integrate new materials into existing regulatory filings and manage global health authority engagement
- Review case studies where early vendor partnerships and cross-functional collaboration enabled successful material transitions in cell and gene therapy pipelines
